Second unanimous FDA adcomm vote boosts bluebird bio
pharmaphorum
JUNE 12, 2022
The panel voted 13 to 0 on the question of whether beti-cel’s benefits outweighed the risks of the gene therapy in patients with beta thalassaemia who are dependent on blood transfusions, in a dream result for the biotech which just a few weeks ago was expressing doubts about its ability to continue as an operating concern.
58 
Let's personalize your content